Jennifer Hamilton

Dr. Hamilton is Vice President and Head of Precision Medicine, Early Clinical Development & Experimental Sciences at Regeneron Pharmaceuticals, Inc., leading a rapidly growing team. She has over 24 years of pharmaceutical industry research experience, 21 of which have been with Regeneron. She has research and/or development experience in inflammation/immune, neurology and oncology indications. As department head, Dr. Hamilton oversees the strategic application of biomarkers for clinical development, including target engagement and disease biomarkers, translational research, life cycle management, pharmacogenetics and predictive medicine, including companion diagnostics, across the entire Regeneron clinical development pipeline and research portfolio (>30 clinical candidates currently in development). The team she manages includes biomarker strategy leads, exploratory data analysts, clinical laboratory operations and companion diagnostic experts. In addition to departmental oversight, Dr. Hamilton also leads several cross-functional translational research initiatives. Dr. Hamilton is known for being an inspirational leader, her collaborative approach, scientific rigor and passion for translational research.

Prior to taking on the departmental leadership role in 2017, Dr. Hamilton led Precision Medicine strategies for a number of development programs, including dupilumab. She was the first person to hold a strategic biomarker position in Global Development at Regeneron, establishing the role and function. Dr. Hamilton’s strategic and scientific contributions include co-championing atopic dermatitis as the lead indication for dupilumab development, as well as eosinophilic esophagitis as an additional indication for the program, both of which have received regulatory approvals worldwide. The translational research vision she implemented across the dupilumab program has provided insight not only into dupilumab mechanism of action in multiple indications, but also contributed to further understanding of the role of IL-4Ra (IL-4/IL-13) and type 2 inflammation in disease. More recently, she has been one of the leaders and contributors to Regeneron’s COVID-19 program strategy and execution.

Prior to joining Regeneron, Jennifer earned an Honors Bachelor’s of Science degree from Purdue University in Genetic Biology; a Ph.D. in Molecular, Cellular, Developmental Biology and Genetics from the University of Minnesota in the Dept. of Laboratory Pathology (studying the neurodegenerative disease spinocerebellar ataxia type 1); and completed a postdoctoral fellowship at Eli Lilly and Co. in Oncology Research (gemcitabine resistance in NSCLC).